How to Get Evenity (Romosozumab) in North Carolina

What Is Romosozumab and Why Does It Matter for NC Patients?

Romosozumab is a humanized monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, romosozumab simultaneously stimulates new bone building and reduces bone resorption, a dual mechanism no other osteoporosis drug replicates 1. The FDA approved Evenity in April 2019 for postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors, or failure of other osteoporosis therapies 2.

North Carolina has roughly 1.2 million women over age 65, and the National Osteoporosis Foundation estimates that 1 in 2 women over 50 will experience an osteoporotic fracture in their remaining lifetime 3. Access barriers in NC include limited endocrinology specialists outside the Research Triangle and Charlotte metro areas, strict prior authorization protocols, and the absence of Medicaid coverage for Evenity. This guide walks through every step required to obtain romosozumab in North Carolina, from the initial DEXA scan to the final injection.

Step 1: Get a DEXA Scan and Baseline Labs

Before any prescriber will write for Evenity, you need a current dual-energy X-ray absorptiometry (DEXA) scan confirming a T-score of −2.5 or below at the lumbar spine, femoral neck, or total hip. The USPSTF recommends screening all women aged 65 and older, and postmenopausal women younger than 65 who have elevated fracture risk 4. DEXA facilities operate in every major NC metro area, and many primary care offices can order the scan directly.

Baseline labs typically include serum calcium, 25-hydroxyvitamin D, a comprehensive metabolic panel, and phosphorus. Hypocalcemia must be corrected before starting romosozumab because the drug can further lower calcium levels 2. The Endocrine Society recommends maintaining serum 25(OH)D above 30 ng/mL before initiating any anabolic osteoporosis therapy 5. If vitamin D is low, most clinicians will prescribe ergocalciferol 50,000 IU weekly for 8 weeks, then recheck levels before proceeding.

Bone turnover markers (P1NP for formation, CTX for resorption) are not mandatory but help track treatment response. P1NP typically peaks within one month of the first romosozumab dose and can serve as an early efficacy signal 6.

Who Can Prescribe Evenity in North Carolina?

Any physician (MD or DO) licensed in North Carolina can prescribe romosozumab. Endocrinologists and rheumatologists prescribe most courses, but orthopedic surgeons and geriatricians also initiate therapy, particularly after fragility fractures. North Carolina nurse practitioners operate under a collaborative practice agreement with a physician and can prescribe Evenity within that agreement's scope 7. Physician assistants in NC prescribe under physician supervision and face no specific drug-class restriction that would exclude romosozumab.

This is a broad prescriber pool. The practical bottleneck is not licensure but familiarity: many primary care providers have never initiated an anabolic bone agent. If your PCP is unfamiliar with romosozumab, ask for a referral to a bone health specialist or explore telehealth options.

Telehealth Prescribing of Evenity in North Carolina

North Carolina permits telehealth prescribing of romosozumab as long as the provider holds a valid NC medical license and establishes a legitimate provider-patient relationship via synchronous audio-video visit 8. The NC Medical Board adopted permanent telehealth rules in 2021, eliminating the requirement for an in-person visit before prescribing most medications.

A telehealth consultation for Evenity typically involves reviewing your DEXA results, fracture history, cardiovascular risk factors, and prior osteoporosis treatments. The provider then submits the prescription electronically to a specialty pharmacy. You still need to receive the actual injection in person (self-injection or clinic administration), but the evaluation, lab review, and prior authorization legwork can happen entirely through telehealth.

Patients in rural NC counties (Robeson, Sampson, Columbus, and others with zero practicing endocrinologists) benefit most from telehealth access. Travel distances to the nearest bone health specialist can exceed 90 miles in parts of southeastern North Carolina, making virtual consultations a practical necessity rather than a convenience.

Prior Authorization: What NC Insurers Require

Almost every insurer covering Evenity in North Carolina requires prior authorization. The documentation package is similar across payers:

1. DEXA scan results showing a T-score at or below −2.5
2. Documentation of high fracture risk (prior fracture, FRAX score, or multiple clinical risk factors)
3. Evidence of failure, intolerance, or contraindication to at least one first-line therapy (typically alendronate or risedronate) 9
4. Baseline calcium and vitamin D levels confirming correction of any deficiency
5. Cardiovascular risk assessment (due to the FDA boxed warning for major adverse cardiac events)

Medicare Part B covers Evenity under the medical benefit when administered in a clinic setting, but requires prior authorization through the Medicare Administrative Contractor for NC (Palmetto GBA). Commercial insurers such as Blue Cross Blue Shield of North Carolina, Aetna, and Cigna each maintain step-therapy protocols that generally demand 12 months of oral bisphosphonate trial or documented intolerance before approving romosozumab 10.

The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone at 24 months 11. Citing this data in the prior authorization letter, along with the patient's individual fracture probability, strengthens the approval case.

North Carolina Medicaid and Evenity

NC Medicaid does not cover Evenity for osteoporosis. The NC Medicaid Preferred Drug List categorizes romosozumab as non-preferred with no published coverage criteria for the osteoporosis indication. Medicaid beneficiaries with severe osteoporosis may need to pursue alternative pathways: Amgen's patient assistance program (Amgen Safety Net Foundation), clinical trial enrollment, or transition to a covered agent such as denosumab (Prolia), which NC Medicaid does cover with prior authorization 12.

This coverage gap affects a significant population. Approximately 2.7 million North Carolinians were enrolled in Medicaid or CHIP as of early 2026, and the state expanded Medicaid eligibility in December 2023 under the ACA expansion.

Specialty Pharmacies and 503A Compounding in NC

Evenity is distributed exclusively through specialty pharmacies. It is not available at retail pharmacies such as CVS, Walgreens, or Rite Aid. Major specialty distributors that ship to North Carolina addresses include Accredo, AllianceRx Walgreens Prime, CVS Specialty, and Biologics by McKesson. Most providers submit the prescription electronically, and the specialty pharmacy coordinates benefits investigation and shipment directly to the patient or administering clinic.

The drug arrives as two prefilled syringes (each containing 105 mg/1.17 mL) that must be stored refrigerated at 2°C to 8°C 2. Both syringes are administered sequentially into the abdomen, thigh, or upper arm to deliver the full 210 mg dose.

North Carolina's Board of Pharmacy licenses 503A compounding pharmacies under state law, and these facilities may prepare patient-specific compounded medications with a valid prescription 13). Romosozumab itself is a biologic monoclonal antibody and is not compounded. No 503A or 503B pharmacy produces a generic or compounded version of romosozumab. Any claim otherwise should be treated with skepticism.

The Cardiovascular Boxed Warning and NC Clinical Practice

The FDA label for Evenity carries a boxed warning based on the ARCH trial's finding that romosozumab-treated patients experienced a higher rate of major adverse cardiovascular events (MACE) compared with alendronate-treated patients (2.5% vs. 1.9% at 12 months) 11. The label contraindicates Evenity in patients who have had a myocardial infarction or stroke within the preceding year 2.

NC prescribers must assess cardiovascular risk before initiating therapy. The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend romosozumab for patients at very high fracture risk, provided they do not have recent cardiovascular events or uncontrolled cardiovascular risk factors 14. A pre-treatment ECG and lipid panel are not universally required but are ordered by many NC cardiologists and endocrinologists as a precaution.

A secondary analysis of the FRAME trial (N=7,180), which compared romosozumab to placebo rather than alendronate, did not show a statistically significant increase in cardiovascular events 15. This distinction matters because the ARCH comparator (alendronate) may itself carry a small cardioprotective effect, making the MACE signal in ARCH partly a comparator-driven finding rather than an absolute risk increase with romosozumab.

What Happens After 12 Months of Romosozumab?

Romosozumab is approved for only 12 monthly doses. Bone mineral density gains peak at month 12 and then begin to decline if no antiresorptive agent follows 16. The standard sequence in clinical practice is 12 months of romosozumab followed by denosumab 60 mg every 6 months or a bisphosphonate (alendronate 70 mg weekly or zoledronic acid 5 mg IV annually).

The DATA extension study showed that patients who received romosozumab for 12 months followed by denosumab for 12 months gained 11.3% BMD at the lumbar spine from baseline, the largest increase documented with any sequential osteoporosis regimen 17. NC patients should plan the transition agent before starting romosozumab, because a gap between completing Evenity and starting an antiresorptive allows rapid bone loss.

Cost, Copay Assistance, and Financial Navigation in NC

The wholesale acquisition cost of Evenity is approximately $1,825 per monthly dose, totaling roughly $21,900 for the full 12-month course. Most commercially insured patients with prior authorization approval face copays ranging from $0 to $200 per injection, depending on plan design.

Amgen offers the Evenity copay card for commercially insured patients, reducing out-of-pocket costs to as low as $5 per dose. Medicare Part B beneficiaries do not qualify for manufacturer copay cards due to federal anti-kickback rules but may apply to the Amgen Safety Net Foundation for assistance. The HealthWell Foundation and the National Osteoporosis Foundation Patient Assistance Fund also provide copay support for qualifying NC residents 3.

NC patients without insurance or with Medicaid (which does not cover Evenity) should contact Amgen's patient access line at 1-888-4EVENITY to explore free drug programs. Approval for these programs typically requires documented income below 300% of the federal poverty level.

Monitoring During and After Treatment in NC

During the 12-month treatment course, the FDA recommends monitoring serum calcium periodically and supplementing calcium 1,000 mg and vitamin D 400 to 800 IU daily 2. A repeat DEXA at 12 months documents the treatment response and establishes the new baseline for the antiresorptive phase. The International Osteoporosis Foundation suggests a treatment target of T-score above −2.5 at the hip, though many patients on romosozumab achieve gains of 5% to 7% at the lumbar spine within 12 months 18.

Bone turnover markers (P1NP, CTX) can be checked at months 1, 6, and 12 to confirm the expected anabolic-then-antiresorptive shift. If P1NP does not rise within the first month, adherence and injection technique should be reassessed. Patients who develop symptoms of hypocalcemia (muscle cramps, paresthesias, perioral numbness) need urgent calcium measurement and supplementation.

Report any new chest pain, neurological symptoms, or sudden-onset jaw pain to your prescriber immediately. Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) have been reported with romosozumab at very low rates in post-marketing surveillance, though neither event occurred at statistically significant rates in the key trials 11.